Pharmacological treatment of obsessive-compulsive disorder / Christopher Pittenger en Psychiatric Clinics of North America, Año 2014 - Vol.37 No. 3 (Septiembre)

Público ISBD [artículo]  inPsychiatric Clinics of North America > Año 2014 - Vol.37 No. 3 (Septiembre) . - pp. 375-391 Título : Pharmacological treatment of obsessive-compulsive disorder Tipo de documento: texto impreso Autores: Christopher Pittenger, Autor ; Michael H. Bloch, Autor Fecha de publicación: 2020 Artículo en la página: pp. 375-391 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Trastorno obsesivo compulsivo, TOC, Farmacoterapia, ISRS, Antidepresivo, Aumento Resumen: Obsessive-compulsive disorder (OCD) affects up to 2.5% of the population of the course of a lifetime and produces substantial morbidity. Approximately 70% of patients can experience significant symptomatic relief with appropriate pharmacotherapy. Selective serotonin reuptake inhibitors are the mainstay of pharmacological treatment. Link: ./index.php?lvl=notice_display&id=24255 [artículo] Pharmacological treatment of obsessive-compulsive disorder [texto impreso] / Christopher Pittenger, Autor ; Michael H. Bloch, Autor . - 2020 . - pp. 375-391. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Psychiatric Clinics of North America > Año 2014 - Vol.37 No. 3 (Septiembre) . - pp. 375-391 Palabras clave: Trastorno obsesivo compulsivo, TOC, Farmacoterapia, ISRS, Antidepresivo, Aumento Resumen: Obsessive-compulsive disorder (OCD) affects up to 2.5% of the population of the course of a lifetime and produces substantial morbidity. Approximately 70% of patients can experience significant symptomatic relief with appropriate pharmacotherapy. Selective serotonin reuptake inhibitors are the mainstay of pharmacological treatment. Link: ./index.php?lvl=notice_display&id=24255

Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: a pilot randomized placebo-controlled trial / Christopher Pittenger en The Journal of Clinical Psychiatry, Año 2015 - Vol.76 - No.8 (Agosto)

Público ISBD [artículo]  inThe Journal of Clinical Psychiatry > Año 2015 - Vol.76 - No.8 (Agosto) . - pp.1075-1084 Título : Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: a pilot randomized placebo-controlled trial Tipo de documento: texto impreso Autores: Christopher Pittenger, Autor ; Michael H. Bloch, Autor ; Suzanne Wasylink, Autor Fecha de publicación: 2020 Artículo en la página: pp.1075-1084 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Terapia farmacológica, Antagonistas de aminoácidos excitatorios, Trastorno obsesivo-compulsivo, Riluzol, Inhibidores de la captación de serotonina. Resumen: Obsessive-compulsive disorder (OCD) affects approximately 2.5% of the population and is associated with significant morbidity. Many patients receive little benefit from the best available treatments, and even those who do respond often suffer from significant residual symptoms. Link: ./index.php?lvl=notice_display&id=21870 [artículo] Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: a pilot randomized placebo-controlled trial [texto impreso] / Christopher Pittenger, Autor ; Michael H. Bloch, Autor ; Suzanne Wasylink, Autor . - 2020 . - pp.1075-1084. Idioma : Inglés (eng) Idioma original : Inglés (eng) in The Journal of Clinical Psychiatry > Año 2015 - Vol.76 - No.8 (Agosto) . - pp.1075-1084 Palabras clave: Terapia farmacológica, Antagonistas de aminoácidos excitatorios, Trastorno obsesivo-compulsivo, Riluzol, Inhibidores de la captación de serotonina. Resumen: Obsessive-compulsive disorder (OCD) affects approximately 2.5% of the population and is associated with significant morbidity. Many patients receive little benefit from the best available treatments, and even those who do respond often suffer from significant residual symptoms. Link: ./index.php?lvl=notice_display&id=21870

---

1 (1 - 2 / 2)